A Review Of ARQ 531
This is the initial NLRP3 inhibitor scientific trial in Parkinson’s so it will be interesting to see what Roche finds inside their information.But there is a good amount of proof for bbb deterioration with age. If carbidopa penetrates that raises the spectre of iatrogenic suppression of dopaminergic signalling. I am not holding my breath the PD e